• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Autism and Developmental Disorders >Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study
【24h】

Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study

机译：低剂量氟伏沙明治疗广泛性发育障碍儿童和青少年的前瞻性开放标签研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The objective of this study was to assess the efficacy and tolerability of low-dose fluvoxamine (1.5 mg/kg/day) in youngsters with pervasive developmental disorders (PDDs). This was a prospective, open-label trial that included 18 subjects with a mean age of 11.3 ± 3.6 years. Fourteen children (78%) completed the 10-week study. Premature discontinuation due to behavioral activation occurred in three participants. Although there was no response for the group as a whole, eight subjects (including all four females) were considered at least partial responders in intent-to-treat analyses. Neither pubertal status nor serotonin levels predicted clinical response. Fluvoxamine can be beneficial in the treatment of select children and adolescents with PDDs. Gender differences in selective serotonin reuptake inhibitor (SSRI) response warrant further investigation.
机译：这项研究的目的是评估低剂量氟伏沙明（1.5 mg / kg /天）在具有普遍性发育障碍（PDD）的年轻人中的疗效和耐受性。这是一项前瞻性开放标签试验，纳入了18名平均年龄为11.3±3.6岁的受试者。 14名儿童（78％）完成了为期10周的研究。由于行为激活而导致的过早中断发生在三名参与者中。尽管整个小组没有任何反应，但在意向性治疗分析中，八名受试者（包括所有四名女性）被认为至少是部分反应者。青春期状态或血清素水平均不能预测临床反应。氟伏沙明对选择治疗PDD的儿童和青少年可能有益。选择性5-羟色胺再摄取抑制剂（SSRI）反应的性别差异值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号